Point-of-Care Testing for Sexually Transmitted Infections
Trial Summary
What is the purpose of this trial?
The proposed research hypothesizes that point-of-care testing (POCT) for sexually transmitted infections (STIs) gonorrhea and chlamydia will be a feasible, acceptable, and appropriate implementation strategy for improving HIV testing and Pre-exposure prophylaxis (PrEP) delivery in youth, by increasing opportunities for clinician-patient counseling, decreasing loss to follow up, and allowing for same-day HIV prevention service provision. This hypothesis will be tested in a pragmatic non-randomized trial comparing clinical (HIV testing and PrEP counseling and prescription) and implementation (feasibility, acceptability, and appropriateness) outcomes between adolescents receiving POCT compared to laboratory-based testing at three clinics within a large pediatric health system.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you have an active PrEP prescription, you would not be eligible to participate.
What data supports the effectiveness of point-of-care testing for gonorrhea and chlamydia?
Point-of-care testing for sexually transmitted infections like gonorrhea and chlamydia is effective because it allows for rapid testing and treatment, which helps control the spread of these infections and prevents complications. This approach is especially beneficial in low-resource areas where traditional lab testing may not be feasible.12345
Is point-of-care testing for sexually transmitted infections safe for humans?
How is point-of-care testing for gonorrhea and chlamydia different from other treatments?
Point-of-care testing for gonorrhea and chlamydia is unique because it allows for rapid diagnosis and early treatment directly at the testing site, which helps prevent the spread of infections and reduces the need for follow-up visits. This is especially beneficial in low-resource areas where traditional lab testing may be delayed due to lack of infrastructure.2461011
Research Team
Sarah Wood, MD, MSHP
Principal Investigator
Mount Sinai Adolescent Health Center
Eligibility Criteria
This trial is for young people aged 16-24 who are being tested for gonorrhea and chlamydia at certain clinics. It's not open to those already known to have HIV or who are actively on PrEP (a medication regimen to prevent HIV).Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive point-of-care or lab-based STI testing and same-day HIV prevention services
Follow-up
Participants are monitored for STI treatment and PrEP counseling outcomes
Treatment Details
Interventions
- Gonorrhea/chlamydia Point-of-Care Testing
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor
Children's Hospital of Philadelphia
Collaborator